These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18998444)

  • 21. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

  • 22. The vexations of Vioxx.
    Sibbald B
    CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046
    [No Abstract]   [Full Text] [Related]  

  • 23. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 24. Perspectives on drug withdrawals.
    Williams R
    CMAJ; 2005 Jul; 173(2):129. PubMed ID: 16027417
    [No Abstract]   [Full Text] [Related]  

  • 25. Seeds of doubt--ADVANTAGE no one.
    Jackson G
    Int J Clin Pract; 2008 Nov; 62(11):1637. PubMed ID: 19143848
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
    Benko LB
    Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
    [No Abstract]   [Full Text] [Related]  

  • 27. Health Canada lukewarm on Vioxx panel findings.
    Murray S
    CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502
    [No Abstract]   [Full Text] [Related]  

  • 28. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 29. New drugs and product approvals from 2000.
    Taylor SE; Gage TW
    Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330
    [No Abstract]   [Full Text] [Related]  

  • 30. Vioxx award good news for Canadian lawsuits.
    Eggertson L
    CMAJ; 2005 Sep; 173(7):744. PubMed ID: 16186576
    [No Abstract]   [Full Text] [Related]  

  • 31. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads.
    Williams M
    Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599
    [No Abstract]   [Full Text] [Related]  

  • 33. Finance fibrillation and research rhythm: do we need a pacemaker?
    Apolone G; Patarnello F
    J Ambul Care Manage; 2008; 31(2):187-9. PubMed ID: 18360180
    [No Abstract]   [Full Text] [Related]  

  • 34. A message from the Vioxx case.
    Baldwin HJ; Droege M; Daniel KL
    Am J Health Syst Pharm; 2006 Mar; 63(6):503. PubMed ID: 16522877
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiac risks with COX-2 inhibitors.
    Ashworth AJ
    CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
    [No Abstract]   [Full Text] [Related]  

  • 36. Open conflict on the handling of the Merck drug Vioxx by editorial giants.
    Edwards RG
    Reprod Biomed Online; 2006 Dec; 13(6):905. PubMed ID: 17169217
    [No Abstract]   [Full Text] [Related]  

  • 37. Beware of new drugs, study suggests.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
    [No Abstract]   [Full Text] [Related]  

  • 38. Few options available for arthritis pain relief. FDA declines to approve Merck's Arcoxia.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(10):1020-2. PubMed ID: 17494894
    [No Abstract]   [Full Text] [Related]  

  • 39. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 40. Hasty approval, more withdrawals.
    Prescrire Int; 2005 Aug; 14(78):144. PubMed ID: 16106597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.